NasdaqGS - Delayed Quote • USD
Compare
At close: 4:00 PM EDT
After hours: 5:12 PM EDT
Line
Candle
Baseline
Mountain
Bar
Loading Chart for GRFS
9/21 12:03 PM
DELL
Date | |
Close | |
Open | |
High | |
Low | |
Volume |
- Previous Close
8.85 - Open
8.92 - Bid 8.23 x 200
- Ask 8.27 x 500
- Day's Range
8.25 - 8.95 - 52 Week Range
5.30 - 12.15 - Volume
3,439,983 - Avg. Volume
1,415,573 - Market Cap (intraday)
6.405B - Beta (5Y Monthly) 0.67
- PE Ratio (TTM)
82.60 - EPS (TTM)
0.10 - Earnings Date May 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Jun 3, 2021
- 1y Target Est
12.07
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.
23,000
Full Time Employees
December 31
Fiscal Year Ends
Healthcare
Sector
Drug Manufacturers - General
Industry
More about Grifols, S.A.
Recent News: GRFS
View MoreAll SEC Filings
Corporate Changes & Voting Matters
Periodic Financial Reports
Proxy Statements
Tender Offer/Acquisition Reports
Offering Registrations
Performance Overview: GRFS
Trailing total returns as of 7/12/2024, which may include dividends or other distributions. Benchmark is IBEX 35...
YTD Return
GRFS
28.55%
IBEX 35...
11.37%
1-Year Return
GRFS
11.85%
IBEX 35...
20.57%
3-Year Return
GRFS
50.39%
IBEX 35...
28.19%
5-Year Return
GRFS
59.98%
IBEX 35...
21.23%
Compare To: GRFS
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
8.26
-6.67%
Mkt Cap 6.405B
Industry Drug Manufacturers—General
51.33
+0.23%
Mkt Cap 128.431B
Industry Drug Manufacturers—General
79.24
+1.67%
Mkt Cap 245.687B
Industry Drug Manufacturers—General
111.70
+1.09%
Mkt Cap 227.914B
Industry Drug Manufacturers—General
69.96
-0.01%
Mkt Cap 87.16B
Industry Drug Manufacturers—General
40.46
-0.71%
Mkt Cap 82.016B
Industry Drug Manufacturers—General
21.30
+2.01%
Mkt Cap 5.478B
Industry Drug Manufacturers—General
230.06
-2.85%
Mkt Cap 33.496B
Industry Drug Manufacturers—General
39.16
+0.67%
Mkt Cap 79.85B
Industry Drug Manufacturers—General
28.92
+0.91%
Mkt Cap 163.878B
Industry Drug Manufacturers—General
127.76
-0.94%
Mkt Cap 323.592B
Industry Drug Manufacturers—General
Statistics: GRFS
View More
Valuation Measures
As of 7/11/2024
Market Cap
6.85B
Enterprise Value
17.11B
Trailing P/E
90.83
Forward P/E
16.18
PEG Ratio (5yr expected)
0.28
Price/Sales (ttm)
0.84
Price/Book (mrq)
0.95
Enterprise Value/Revenue
2.40
Enterprise Value/EBITDA
13.37
Financial Highlights
Profitability and Income Statement
Profit Margin
2.84%
Return on Assets (ttm)
2.30%
Return on Equity (ttm)
3.48%
Revenue (ttm)
6.66B
Net Income Avi to Common (ttm)
189M
Diluted EPS (ttm)
0.10
Balance Sheet and Cash Flow
Total Cash (mrq)
608.92M
Total Debt/Equity (mrq)
140.31%
Levered Free Cash Flow (ttm)
-1.51B
Research Analysis: GRFS
View MoreCompany Insights: GRFS
Research Reports: GRFS
View MorePeople Also Watch
IRWD Ironwood Pharmaceuticals, Inc.
6.48
-5.12%
HCM HUTCHMED (China) Limited
19.40
+9.11%
LIVN LivaNova PLC
51.43
-1.89%
FMS Fresenius Medical Care AG
19.91
+0.35%
GLPG Galapagos NV
27.00
-0.07%
ARGX argenx SE
466.42
+1.02%
ENTA Enanta Pharmaceuticals, Inc.
16.00
+6.74%
PCRX Pacira BioSciences, Inc.
21.76
-0.23%
ZLAB Zai Lab Limited
18.04
+1.12%
RARE Ultragenyx Pharmaceutical Inc.
45.14
+2.85%
APLS Apellis Pharmaceuticals, Inc.
39.53
+1.65%
BGNE BeiGene, Ltd.
152.17
+1.11%
PTCT PTC Therapeutics, Inc.
33.27
+0.21%
GMAB Genmab A/S
27.05
+3.09%
DNLI Denali Therapeutics Inc.
22.86
-1.00%
CTLT Catalent, Inc.
57.58
-0.84%